3 High-Yield Dividend Stocks to Buy in May: GlaxoSmithKline, A.P. Moeller-Maersk, and ENI

NYSE: GSK | GSK PLC ADR News, Ratings, and Charts

GSK – With the latest federal interest rate hike and the possibility of further monetary policy tightening, market indices have been going haywire. Because volatility is expected to persist, with experts fearing the economy will slip into recession, we think it could be wise to bet on high dividend-yielding stocks GlaxoSmithKline (GSK), A.P. Møller – Mærsk (AMKBY), and Eni (E) to generate a steady income stream. Let’s discuss.

The stock market experienced a freefall yesterday to register its worst day of losses this year, following the prior day’s rally after the Fed raised interest rates by 50 basis points. Worries about the economy slipping into recession with the Fed’s monetary tightening precipitated the selloff. CNBC’s Jim Cramer said, “Right now, I think a curious mind would be buying stocks selectively, not selling them indiscriminately.” Caution is therefore the theme until the market absorbs a high interest-rate environment.

Investors looking to dodge potential market fluctuations on lingering concerns over macroeconomic and geopolitical issues could bet on high-yielding dividend stocks now. The ability to pay high dividends amid such uncertainties indicates their financial strength, which could help them stay afloat. Furthermore, investors could generate a steady income stream because of their dividend payouts. Investors’ interest in high-dividend stocks is evident in the iShares Core High Dividend ETF’s (HDV) 6.5% returns over the past six months.

Therefore, we think high dividend-yielding stocks GlaxoSmithKline plc (GSK), A.P. Møller – Mærsk A/S (AMKBY), and Eni S.p.A. (E) could be safer bets at this juncture.

GlaxoSmithKline plc (GSK)

Headquartered in Brentford, U.K., GSK, and its subsidiaries create, discover, develop, manufacture, and market pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the U.K., the U.S., and internationally. Its four segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines; and Consumer Healthcare. 

On April 27, 2022, Emma Walmsley, GSK’s CEO, said, “Our results reflect further good momentum across specialty medicines and vaccines, including the return to strong sales growth for Shingrix and continuing pipeline progress. We also continue to see very good momentum in Consumer Healthcare, demonstrating strong potential of this business ahead of its proposed demerger in July, to become Haleon.”

GSK has been paying dividends for 13 consecutive years. GSK’s dividend payouts have grown at a 10.9% CAGR over the past three years. Its current dividend translates to a 4.87% yield, while its four-year average yield is 5.22%. On May 4, 2022, GSK declared a quarterly dividend of $0.35 per share.

GSK’s turnover came in at £9.78 billion ($12.08 billion) for the first quarter, ended March 31, 2022, up 31.8% year-over-year. Its operating profit came in at £2.80 billion ($3.46 billion), up 65.4% year-over-year. Also, the company’s profit attributable to shareholders increased 67.9% year-over-year to £1.80 billion ($2.23 billion), while its EPS came in at 35.60p, up 67.1% year-over-year.

GSK’s revenue is expected to increase 2.3% to $46.93 billion in 2023. Its EPS is estimated to increase 8.2% per annum over the next five years. It surpassed EPS estimates in each of the trailing four quarters. Over the past year, the stock has gained 17.5% in price to close yesterday’s trading session at $44.39.

GSK’s POWR Ratings reflect this promising outlook. The stock has an overall B rating, which equates to a Buy in our POWR Ratings system. The POWR Ratings assess stocks by 118 distinct factors, each with its own weighting.

It has a B grade for Value and Stability. It is ranked #11 of 167 stocks in the Medical – Pharmaceuticals industry. Click here to see the additional ratings for GSK (Growth, Momentum, Sentiment, and Quality).

Click here to checkout our Healthcare Sector Report for 2022

A.P. Møller – Mærsk A/S (AMKBY)

Based in Copenhagen, Denmark, AMKBY operates worldwide as an integrated transport and logistics company. Its segments are Ocean; Logistics & Services; Terminals & Towage; and Manufacturing & Others.

On May 4, 2022, AMKBY’s CEO, Søren Skou said, “In Q1 we delivered the best earnings quarter ever in A.P. Moller – Maersk with growth across Ocean, Logistics and Terminals. The increased earnings are driven by freight rates and by contracts being signed at higher levels. While global supply chains remain under significant pressure, we continue to demonstrate superior ability to help customers overcome logistic challenges.”  

AMKBY has been paying dividends for nine consecutive years. AMKBY’s dividend payouts have grown at a 154.2% CAGR in the past three years. Its current dividend translates to a 12.25% yield, while its four-year average yield is 5.70%.

AMKBY’s revenue increased 55.1% year-over-year to $19.29 billion for the first quarter, ended March 31, 2022. Its EBIT came in at $7.27 billion, up 134.8% year-over-year. The company’s cash flow from operating activities came in at $8.22 billion, compared to $3.43 billion, for the same period.

Analysts expect AMKBY’s revenue to be $75.36 billion for its fiscal period ending Dec. 31, 2022, representing a 22% year-over-year rise. Over the past year, the stock gained 16.4% in price to close yesterday’s session at $15.11.

It is no surprise that AMKBY has an overall A rating, which equates to a Strong Buy in our POWR Rating system.

It has an A grade for Growth and Value and a B grade for Momentum and Quality. It is ranked first in the A-rated Shipping industry. Click here to see the additional POWR Ratings for Stability and Sentiment for AMKBY.

Eni S.p.A. (E)

Headquartered in Rome, Italy, E explores, develops, and produces crude oil and natural gas. It operates through Exploration & Production; Global Gas & LNG Portfolio; Refining and Marketing and Chemicals; Plenitude and Power; and Corporate and Other activities segments.

E has been paying dividends for more than 12 consecutive years. Its current dividend translates to a 6.57% yield, while its four-year average yield is 6.17%.

For the first quarter, ended March 31, 2022, E’s adjusted operating profit increased 293% year-over-year to €5.19 billion ($5.49 billion). Its adjusted net profit came in at €3.27 billion ($3.46 billion), up 1,111.1% year-over-year, while its EPS came in at €0.91, up 1,037.5% year-over-year.

E’s revenue is expected to increase 20.9% year-over-year to $104.84 billion for the fiscal period ending Dec. 31, 2022. Its EPS is estimated to increase 19.5% per annum for the next five years. Over the past year, the stock has gained 14.7% in price to close yesterday’s trading session at $28.49.

It is no surprise that E has an overall A rating, which equates to a Strong Buy in our proprietary rating system. In addition, it has an A grade for Momentum and a B grade for Growth and Sentiment.

E is ranked #5 of 42 stocks in the A-rated Foreign Oil & Gas industry. Click here to see the additional POWR Ratings for E (Value, Stability, and Quality).

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year

Top 10 Stocks for 2022

Bear Market Scare? Read Before Your Next Trade

7 SEVERELY Undervalued Stocks


GSK shares were trading at $44.18 per share on Friday morning, down $0.21 (-0.47%). Year-to-date, GSK has gained 1.59%, versus a -12.95% rise in the benchmark S&P 500 index during the same period.


About the Author: Riddhima Chakraborty


Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
GSKGet RatingGet RatingGet Rating
AMKBYGet RatingGet RatingGet Rating
EGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Bullish or Bearish Stock Set Up?

The S&P 500 (SPY) record highs sounds pretty darn bullish on the surface. Yet as we dig below the surface there are some curious signals that point more Risk Off. This is especially true as we come into the next Fed meeting after a round of data that points to inflation still being too high...only further delaying the first rate cut. What does this all mean for stocks from here? Steve Reitmeister offers his latest views on the market outlook along with a preview of his top picks to stay on step ahead of the market. Read on for more...

3 High-Yield Dividend Stocks to Boost Your Portfolio

Even though inflation appears to be cooling down, it still remains above the Fed’s 2% target. Amid ongoing geopolitical tensions, investors could consider looking into high-yield dividend stocks, Verizon Communications (VZ), Altria Group (MO), and Ares Capital (ARCC). Keep reading...

3 Fintech Stocks Revolutionizing Financial Services

Fintech is causing a revolutionary shift in the financial services market and this could be the right time to scoop up fundamentally strong fintech stocks like PayPal Holdings (PYPL), NerdWallet (NRDS), and Qifu Technology (QFIN). Read more...

3 Value Stocks With Strong Fundamentals to Buy Now

Value investing is highly favored as it focuses on purchasing undervalued stocks with solid fundamentals, providing the potential for high returns with lower risk and a disciplined, long-term approach. Therefore, it could be wise to invest in fundamentally sound, value stocks Expedia Group (EXPE), Incyte (INCY), and Albertsons Companies (ACI) for substantial long-term returns. Keep reading...

Stock Alert: Breakout or Fake Out?

The S&P 500 (SPY) officially made new highs this week. Perhaps a reason to celebrate more gains on the way...or perhaps there are signs this move is hollow leading to more downside soon on the way. To help solve this riddle, 44 year investment veteran Steve Reitmeister shares his views along with a trading plan and top picks to stay on the right side of the action. That is what Steve Reitmeister will cover in his latest commentary below. Read on for more...

Read More Stories

More GSK PLC ADR (GSK) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All GSK News